Market Research Logo

Global Retinal Drugs Market 2018-2022

About Retinal Drugs

Retinal drugs are the medications that are used for the treatment of retinal diseases.

Technavio’s analysts forecast the global retinal drugs market to grow at a CAGR of 7.63% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global retinal drugs market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Retinal Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • ALLERGAN
  • Bayer
  • F. Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals
  • Valeant Pharmaceuticals
Market driver
  • Rise in the prevalence of retinal diseases
  • For a full, detailed list, view our report
Market challenge
  • High cost associated with retinal disease therapy
  • For a full, detailed list, view our report
Market trend
  • Development of innovative therapies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?


Press Release

Technavio Announces the Publication of its Research Report – Global Retinal Drugs Market 2018-2022

Technavio recognizes the following companies as the key players in the global retinal drugs market: ALLERGAN, Bayer, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, and Valeant Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is development of innovative therapies. Researchers are focusing on the development of advanced technologies such as gene therapy, eye drops, radiation, and stem cells for the treatment of retinal diseases. Additionally, companies are also focusing on developing combination therapies for the treatment of retinal diseases.”

According to the report, one driver in the market is rise in the prevalence of retinal diseases. It has been observed that the prevalence of retinal diseases such as RVO, mCNV, diabetic retinopathy, wet AMD, and DME is high in both the developing and developed countries. One of the leading causes of visual disability in the industrialized countries is AMD.

Further, the report states that one challenge in the market is high cost associated with retinal disease therapy. The high cost of retinal drugs is limiting their widespread adoption, and in turn, inhibiting their market growth. EYLEA costs approximately $1,850 per intravitreal dose, LUCENTIS 0.5 mg costs approximately $2,000 per dose, and conbercept costs approximately $1,150 per dose.

Companies Mentioned

ALLERGAN, Bayer, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, and Valeant Pharmaceuticals.

  • Executive summary
  • Scope of the report
  • Research methodology
  • Market landscape
    • Market ecosystem
      • Table Parent market
      • Table Global ophthalmic drugs market segmentation
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2017
      • Table Market size 2017
      • Table Validation techniques employed for market sizing 2017
    • Market size and forecast 2017-2022
      • Table Global retinal drugs market - Market size and forecast 2017-2022 ($ mn)
      • Table Global retinal drugs market - Year-over-year growth 2018-2022 (%)
  • Five forces analysis
    • Table Five forces analysis 2017
    • Table Five forces analysis 2022
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2017
  • Market segmentation by indication
    • Segmentation by indication
      • Table Global retinal drugs market - Market share by indication 2017-2022 (%)
    • Comparison by indication
      • Table Comparison by indication
    • MD drugs
      • Table Global MD drugs market - Market size and forecast 2017-2022 ($ mn)
      • Table Global MD drugs market - Year-over-year growth 2018-2022 (%)
    • DED drugs
      • Table Global DED drugs market - Market size and forecast 2017-2022 ($ mn)
      • Table Global DED drugs market - Year-over-year growth 2018-2022 (%)
    • Others
      • Table Global other retinal diseases drugs market - Market size and forecast 2017-2022 ($ mn)
      • Table Global other retinal diseases drugs market - Year-over-year growth 2018-2022 (%)
    • Market opportunity by indication
      • Table Market opportunity by indication
  • Market segmentation by drug class
    • Segmentation by drug class
      • Table Global retinal drugs market share by drug class 2017 (%)
    • Anti-VEGF agents
      • Table Major anti-VEGF agents approved in the market
    • Corticosteroids
      • Table Major corticosteroids approved in the market
    • Others
  • Customer landscape
    • Table Customer landscape
  • Regional landscape
    • Geographical segmentation
      • Table Global retinal drugs market - Market share by geography 2017-2022 (%)
    • Regional comparison
      • Table Regional comparison
    • Retinal drugs market in Americas
      • Table Retinal drugs market in Americas - Market size and forecast 2017-2022 ($ mn)
      • Table Retinal drugs market in Americas - Year-over-year growth 2018-2022 (%)
      • Table Top 3 countries in Americas
    • Retinal drugs market in EMEA
      • Table Retinal drugs market in EMEA - Market size and forecast 2017-2022 ($ mn)
      • Table Retinal drugs market in EMEA - Year-over-year growth 2018-2022 (%)
      • Table Top 3 countries in EMEA
    • Retinal drugs market in APAC
      • Table Retinal drugs market in APAC - Market size and forecast 2017-2022 ($ mn)
      • Table Retinal drugs market in APAC - Year-over-year growth 2018-2022 (%)
      • Table Top 3 countries in APAC
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
  • Market trends
    • Development of innovative therapies
    • Rise in demand for sustained-release ocular formulations
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • ALLERGAN
      • Table ALLERGAN – Overview
      • Table ALLERGAN - Business segments
      • Table ALLERGAN - Organizational developments
      • Table ALLERGAN - Geographic focus
      • Table ALLERGAN - Segment focus
      • Table ALLERGAN - Key offerings
      • Table ALLERGAN - Key customers
    • Bayer
      • Table Bayer – Overview
      • Table Bayer - Business segments
      • Table Bayer - Organizational developments
      • Table Bayer - Geographic focus
      • Table Bayer - Segment focus
      • Table Bayer - Key offerings
      • Table Bayer - Key customers
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche – Overview
      • Table F. Hoffmann-La Roche - Business segments
      • Table F. Hoffmann-La Roche - Organizational developments
      • Table F. Hoffmann-La Roche - Geographic focus
      • Table F. Hoffmann-La Roche - Segment focus
      • Table F. Hoffmann-La Roche - Key offerings
      • Table F. Hoffmann-La Roche - Key customers
    • Novartis
      • Table Novartis – Overview
      • Table Novartis - Business segments
      • Table Novartis - Organizational developments
      • Table Novartis - Geographic focus
      • Table Novartis - Segment focus
      • Table Novartis - Key offerings
      • Table Novartis - Key customers
    • Regeneron Pharmaceuticals
      • Table Regeneron Pharmaceuticals – Overview
      • Table Regeneron Pharmaceuticals - Business segments
      • Table Regeneron Pharmaceuticals - Organizational developments
      • Table Regeneron Pharmaceuticals - Geographic focus
      • Table Regeneron Pharmaceuticals - Segment focus
      • Table Regeneron Pharmaceuticals - Key offerings
      • Table Regeneron Pharmaceuticals - Key customers
    • Valeant Pharmaceuticals
      • Table Valeant Pharmaceuticals – Overview
      • Table Valeant Pharmaceuticals - Business segments
      • Table Valeant Pharmaceuticals - Organizational developments
      • Table Valeant Pharmaceuticals - Geographic focus
      • Table Valeant Pharmaceuticals - Segment focus
      • Table Valeant Pharmaceuticals - Key offerings
      • Table Valeant Pharmaceuticals - Key customers
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report